

# BIOMARKERS OF NEOPLASTIC TRANSFORMATION IN CANINE SPIROCERCOSIS

by

## **Eran Dvir**

Submitted to the Faculty of Veterinary Science, University of Pretoria, in partial fulfilment of the requirements for the degree of

**Doctor of Philosophy** 

Department of Companion Animal Clinical Studies Faculty of Veterinary Science University of Pretoria

Pretoria, June 2012



#### Biomarkers of neoplastic transformation in canine spirocercosis

By : Prof. E Dvir

Department of Companion Animal Clinical Studies

Faculty of Veterinary Science

University of Pretoria

South Africa

Supervisor : Prof. J P Schoeman

Department of Companion Animal Clinical Studies

Faculty of Veterinary Science

University of Pretoria

South Africa

Co-supervisor : Dr R J Mellanby

Division of Veterinary Clinical Studies

Royal (Dick) School of Veterinary Studies

University of Edinburgh

United Kingdom



I, Eran Dvir, hereby declare that the work on which this thesis is based, is original and that neither the whole work nor any part of it has been, is being, or is to be submitted for another degree at this or any other University, Tertiary Education Institution, or Examining Body.

10 May 2012



# **TABLE OF CONTENTS**

		Page
TABLE	OF CONTENTS	vi
SUMM	SUMMARY	
ACKNO	ACKNOWLEDGMENTS	
ABBRE	EVIATIONS	xiii
TABLE	S	XV
FIGUR	E	xvi
CHAPT	TER ONE: BACKGROUND	1
1.1	Canine spirocercosis	1
1.2	Spirocerca lupi-induced sarcoma	2
1.3	Inflammation / Infection-induced cancer	3
1.4	Helminth-induced inflammation and cancer	5
1.5	Cancer biomarkers	7
1.6	Diagnosis of neoplastic vs. non-neoplastic spirocercosis	8
CHAPT	CHAPTER TWO: RESEARCH HYPOTHESES	
CHAPT	ER THREE: GENERAL METHODOLOGY	11
3.1	Cases	11
3.1.1	Retrospective cases	11
3.1.2	Prospective cases	12
3.2	Samples	12
3.2.1	Histopathology	12



## 3.2.2 Plasma

	R FOUR: CLINICAL DIFFERENTIATION BETWEEN DOGS WITH AND MALIGNANT SPIROCERCOSIS	4.4
		14
4.1	Abstract	15
4.2	Introduction	16
4.3	Material and Methods	18
4.4	Results	20
4.4.1	Signalment	20
4.4.2	Clinical presentation	20
4.4.3	Haematology	21
4.4.4	Serum proteins	21
4.4.5	Radiology	22
4.5	Discussion	23
4.6	Tables	30
4.7	Figures	34
CHAPTE	R FIVE: PROPOSED HISTOLOGICAL PROGRESSION OF THE	
SPIROC	ERCA LUPI-INDUCED OESOPHAGEAL LESION IN DOGS	37
5.1	Abstract	37
5.2	Introduction	38
5.3	Material and Methods	42
5.3.1	Data analysis	45
5.3.2	Further analysis and grading	45



5.4	Results	46
5.5	Discussion	48
5.6	Tables	54
5.7	Figures	56
CHAPTER SIX: EVALUATION OF SELECTED GROWTH FACTOR EXPRESSION IN CANINE SPIROCERCOSIS (SPIROCERCA LUPI)-ASSOCIATED NON-NEOPLASTIC NODULES AND SARCOMAS		
6.1	Abstract	61
6.2	Introduction	62
6.3	Material and Methods	65
6.3.1	Case selection	65
6.3.2	Controls	66
6.3.3	Immunohistochemistry	67
6.3.4	Scoring of immunoreactivity	68
6.3.5	Assessment of microvessel density (MVD)	68
6.3.6	Statistical analysis	69
6.4	Results	69
6.4.1	Growth factor immunohistochemistry	69
6.4.2	Labelling of the positive-tissue control	69
6.4.3	VEGF labelling of fibroblasts and tumour cells	70
6.4.4	FGF labelling of fibroblasts and tumour cells	71
6.4.5	PDGF labelling of fibroblasts and tumour cells	71



6.4.6	Microvessel density	72
6.5	Discussion	73
6.6	Conclusions	79
6.7	Tables	80
6.8	Figures	82
CHAPTER SEVEN: IMMUNOHISTOCHEMICAL CHARACTERIZATION OF LYMPHOCYTE AND MYELOID CELL INFILTRATES IN SPIROCERCOSIS-INDUCED OESOPHAGEAL NODULES		
7.1	Abstract	90
7.2	Introduction	91
7.3	Materials and Methods	93
7.3.1	Case selection	93
7.3.2	Immunohistochemical labelling of FoxP3, CD3, Pax5 and Myeloid/Histiocyte antigen MAC387	94
7.3.3	Scoring of IHC labelling	95
7.3.4	Statistical analysis	96
7.4	Results	96
7.5	Discussion	98
7.6	Tables	103
7.7	Figures	109
CHAPTER 8: PLASMA IL-8 AND IL-18 CONCENTRATIONS ARE INCREASED IN DOGS WITH SPIROCERCOSIS		
8.1	Abstract	112



8.2	Introduction	113
8.3	Materials and Methods	118
8.3.1	Study population	118
8.3.2	Patient sampling	119
8.3.3	Analyses	120
8.3.4	Data analysis	120
8.4	Results	120
8.5	Discussion	121
8.6	Tables	126
CHAPTER NINE: GENERAL DISCUSSION AND CONCLUSIONS		127
CHAPTER TEN: REFERENCES		132
СНАРТЕ	ER ELEVEN: APPENDICES	142
11.1	List of journal publications of work directly related to this thesis	142
11.2	List of journal publications of work in the same study area, but not directly related to this thesis	143
11.3	List of conference presentations directly related to this thesis	144
11.3.1	Keynote addresses	144
11.3.2	Research abstracts	145



## **SUMMARY**

Spirocerca lupi is a nematode that infects the dog's oesophagus and promotes the formation of an inflammatory fibroblastic nodule that progresses to sarcoma in approximately 25% of cases. Differentiating neoplastic from non-neoplastic cases ante-mortally is challenging and has major therapeutic and prognostic implications. More importantly, spirocercosis-associated oesophageal sarcoma is an excellent and under-utilized spontaneous model of parasite-associated malignancy and the pathogenesis of the neoplastic transformation is poorly understood.

The current study objective was to investigate potential clinical, clinicopathological, radiological and tissue biomarkers for the malignant transformation and an attempt to use these biomarkers to gain a deeper understanding of the pathogenesis of the neoplastic transformation. Our central hypothesis was that the parasite produces excretory product(s) which diverts the immune response from a T helper 1 (Th1) to Th2 cell response, typical of many nematode infections, and further to an immunoregulatory (immunosuppressive), FoxP3+ regulatory T cell-predominated response which then facilitates neoplastic transformation.

The following parameters were studied and compared between cases with non-neoplastic and neoplastic spirocercosis: clinical presentation, haematology, serum albumin and globulin, thoracic radiology, haematoxylin-eosin (H&E) histology, Immunohistochemistry for expression of vascular endothelial growth factor (VEGF)-A, fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), MAC387 (myeloid cells), CD3 (T cells), Pax5 (B cells) and FoxP3 (T regulatory cells) and plasma cytokine concentrations including IL-2, IL-4, IL-6, IL-8, IL-10, IL-18, GM-CSF and MCP-1.



Hypertrophic osteopathy showed 100% specificity for neoplastic transformation but relatively poor sensitivity (40%). Female gender, anaemia, leukocytosis, thrombocytosis, spondylitis and bronchial displacement were significantly more common in neoplastic cases, but appeared in non-neoplastic cases as well. The H&E study revealed 2 stages in the non-neoplastic nodules: early inflammation, characterized by fibrocytes and abundant collagen, and a pre-neoplastic stage, characterized by activated fibroblasts and reduced collagen. The neoplastic cases were all sarcomas, primarily osteosarcoma with very aggressive features comparable to other appendicular osteosarcoma in the dog. The inflammation in spirocercosis is characterized by pockets of pus (MAC387+ cells) surrounded by organized lymphoid foci (CD3+ and to a lesser degree Pax5+ cells). There was no evidence of a local accumulation of FoxP3+ cells, unlike many previous studies which have reported an increase in Foxp3+ T cells in both malignancies and parasite infections. Interleukin-8 plasma concentration was higher in the neoplastic group compared to the nonneoplastic and the control groups. Interleukin-18 concentration was higher in the nonneoplastic group followed by the control group and finally the neoplastic group. As with most similar studies, no ideal biomarker with high sensitivity and specificity was identified. However, if examined together, a panel of the biomarkers that were identified more commonly in the neoplastic cases should substantially increase the index of suspicion for neoplastic transformation in a diagnosed spirocercosis case. The inflammatory response showed features of increased myeloid (innate) response and lymphocytic response with pro-inflammatory cytokines. This was not our initial hypothesis and the question remains whether the response is secondary to the worm infection, or to a symbiotic bacterium that is carried by the worm. The role of such a reaction in neoplastic transformation remains to be elucidated.



## **ACKNOWLEDGEMENTS**

This study was funded by Petplan Charitable Trust, the European College of Veterinary Internal Medicine – Companion Animal (ECVIM-CA) Clinical Research Fund, Duncan Campbell Memorial Fund of the South African Veterinary Foundation (SAVF) and several research funds within the Faculty of Veterinary Science in the University of Pretoria, South Africa (including the Department of Companion Animal Clinical Studies, the section of Pathology within the Department of Paraclinical studies and the Faculty research fund).

I would like to express my gratitude to the following people:

- ➤ Srs. Carla van der Merwe, Marizelle DeClerq and Liani Kitshoff of the Onderstepoort Veterinary Academic Hospital (OVAH) for their help in the administration and organisation of the patients and procedures required.
- ➤ Carien Muller, Cheryl Pretorius and the other staff in the Clinical Pathology laboratory in the OVAH for their help in the samples preparation and storage.
- ➤ Marie Smit in the Immunohistochemistry laboratory in the Faculty of Veterinary Science in the University of Pretoria for her role in the immunohistochemistry staining of the growth factors.
- ➤ Jeanie Finlayson, Dr Julio Benavides and the Histopathology laboratory at Moredun Research Institute, and Neil McIntyre at the Royal (Dick) School of Veterinary Studies, Edinburgh, UK for their assistance with the immunohistochemical staining and analysis of the inflammatory cells.
- My colleagues in the section of Small Animal Medicine for their support and hard work on the clinic floor while I was engaged in this project.



- ➤ To my residents and my colleagues in the *Spirocerca lupi* research group: Drs. Varaidzo Mukorera, Paolo Pazzi, Chantal Rosa, Liesel L van der Merwe, J Christie and Prof. Robert M Kirberger for their contribution to the clinical management of the cases. Together we made one of the most productive and vibrant research groups in the Faculty.
- ➤ My co-authors on the five publications that came out of this PhD: Profs.

  Robert M Kirberger, Mark C Williams and Johan P Schoeman and Drs.

  Varaidzo Mukorera, Liesel L van der Merwe, Sarah J Clift, Tom N. McNeilly,

  Richard J. Mellanby and Mads Kjelgaard-Hansen.
- ➤ Prof. Piet Stadler, the former head of department for his support at the beginning of the project.
- ➤ My dear friend and my colleague, Prof. Robert M Kirberger, for the continuous support, endless patience, good advices and example of how to combine clinical work with meaningful research.
- ➤ My research supervisors, colleagues and friends, Prof. Johan P Schoeman and Dr. Richard J Mellanby for their advice, support and enthusiasm for the project. They have turned obstacles into opportunities to make this project successful.
- Last but not least, to my family, my mother Aliza, my wife Leah and my beautiful two children Yarden and Omer. Their endless support as they went along with their daily life made this project most enjoyable.



## **ABBREVIATIONS**

S. lupi – Spirocerca lupi

µg – microgram

μl – microlitre

BSA - bovine serum albumin

BVSc – Bachelor of Veterinary Science

C – Celsius

C – Collagen

CD - Cluster of differentiation

CRP- C-reactive protein

dl – decilitre

DL – detection limit

DN - degenerate neutrophils

DNA - deoxyribonucleic acid

DVM - Doctor of Veterinary Medicine

Dipl. ECVIM-CA - Diplomate of the European College of Veterinary Internal Medicine

Companion Animals

ED – Eran Dvir

EDTA - Ethylenediaminetetraacetic acid

F – fibroblast

FGF - fibroblast growth factor

Fig. - figure

FoxP3 - Forkhead box P3

GM-CSF - granulocyte-macrophages colony-stimulated factor

H& E / HE - Haematoxylin-eosin

HO - Hypertrophic osteopathy

Hons - Honours

Ht - Haematocrit

IHC – immunohistochemistry

IL - Interleukin

kg – kilogram

L1-5 – Larvae life cycle stage number

LP – lymphocytic-plasmacytic

LSAB - labelled steptavidin-biotin

MAC 387 - Macrophage marker

MCP - monocyte chemotactic protein

Martius, Scarlet and Blue - MSB

MCV - mean corpuscular volume

MCW - Mark C Williams

NF-κB - nuclear factor kappa-light-chain-enhancer of activated B cells

NGS – normal goat serum

Mi - mitoses



ml - millilitre

mm - milimeter

MMedVet - Master in Veterinary Medicine

MN – multinucleated

MVD- Microvessel density

O – osteoblasts

Osm – osteoid matrix

OVAH - Onderstepoort Veterinary Academic Hospital

p – probability

Pax5 - Paired box protein 5

PBS - phosphate buffer

PBST80 - phosphate-buffered saline (PBS) containing 0.5% Tween 80

PDGF - platelet-derived growth factor

pH - power of hydrogen

pg – picogram

RK – Robert Kirberger

RT – room temperature

S. lupi – Spirocerca lupi

SC – subcutaneous

SJC - Sarah J Clift

T – temperature

T1-12 – Thoracic vertebrae number

TGF - Transforming growth factor

Th1 - T helper type

Tregs - T regulatory cells

VEGF - vascular endothelial growth factor

UK – United Kingdom

vs – versus

WBC - White blood cell count

μg – microgram

 $\mu l - microlitre$ 

 $\chi^2$  - Chi-square



# **TABLES**

		Page
Tables	s – Chapter 4	
Table 1	Gender differences between benign and malignant groups	30
Table 2	Prevalence differences of clinical signs between the benign and	
	malignant groups	31
Table 3	Haematology differences between the benign and malignant groups	32
Table 4	Radiological differences between the benign and malignant groups	33
Tables	s – Chapter 5	
Table 1	Histological parameters in the non-neoplastic groups	54
Table 2	Frequencies of histological scores of neoplastic variables in the 20	
	cases with spirocercosis-induced sarcoma	55
Tables	s – Chapter 6	
Table 1	Expression of VEGF, bFGF & PDGF in spirocercosis-associated	
	nodule	80
Table 2	Non specific VEGF, FGF and PDGF labelling observed in cells other	
	than fibroblasts and tumour cells	81
Tables	s – Chapter 7	
Table 1	Scoring system for CD3+ and Pax5+ infiltrates	103
Table 2	Scoring system for MAC387+ infiltrates	103
Table 3	Leukocyte prevalence in the different groups	104



	Table 4	Nodule distribution and score of MAC387+ cells	104
	Table 5	Nodule distribution and score of CD3+ cells	105
	Table 6	Nodule distribution and score of Pax5+ cells	106
	Table 7	Lymphocyte prevalence in the different study groups	107
	Table 8	The number of FoxP3+ cells per 0.0625mm <sup>2</sup> in the different groups	107
	Table 9	Number of T regulatory cells per 0.0625mm <sup>2</sup> in the lymph nodes of	
		the different groups	108
Tables – Chapter 8			
	Table 1	The different cytokines plasma concentrations (pg/ml) in the different	
		groups	125



## **FIGURES**

		Page
Figures	s – Chapter 4	
Figure 1	Mediolateral view of the tibia of a six year old Staffordshire bull	
	terrier with hypertrophic osteopathy	34
Figure 2	Medial-lateral (A) and ventro-dorsal (B) thoracic radiographs	35
Figure 3	Oesophageal endoscopic pictures of neoplastic nodule (A) and	
	benign nodule (B)	36
Figures	s – Chapter 5	
Figure 1	Florid lymphoplasmacytic cell infiltrate within a non-neoplastic	
	oesophageal nodule (pre-neoplastic / stage 2), H&E.	56
Figure 2	Spirocerca lupi larva surrounded by a rim of necrotic cell debris and	
	degenerate neutrophils within a non-neoplastic oesophageal nodule.	
	H&E.	56
Figure 3	Spirocerca lupi egg surrounded by degenerate neutrophils,	
	occasional fibroblasts and haemorrhage within a non-neoplastic	
	oesophageal nodule. H&E	57
Figure 4	Purulent exudate (associated with Spirocerca lupi worm and tract)	
	within a non-neoplastic oesophageal nodule. H&E.	57
Figure 5	Collagen, fibrocytes and intervening lymphoplasmacytic cell	
	infiltrate within a non-neoplastic oesophageal nodule. H&E.	58
Figure 6	Fibranlasia within a non-neonlastic aesanhageal nodule H&F	58



Figure 7	Well-differentiated oesophageal osteosarcoma . Neoplastic pyriform	
	osteoblasts in association with osteoid matrix and mineralized bone.	
	H&E.	59
Figure 8	Poorly-differentiated oesophageal fibrosarcoma. Neoplastic spindle-	
	shaped cells showing nuclear atypia amidst multinucleated cells and	
	mitoses. H&E.	59
Figures	– Chapter 6	
Figure 1A	Positive VEGF control; granulation tissue in a dog	82
Figure 1B	VEGF labelling of S. lupi-associated oesophageal osteosarcoma	82
Figure 1C	VEGF labelling of S. lupi-associated pre-neoplastic nodule	82
Figure 1D	FGF labelling of S. lupi-associated oesophageal osteosarcoma	82
Figure 1E	FGF labelling of S. lupi-associated pre-neoplastic nodule	82
Figure 1F	PDGF labelling of <i>S. lupi</i> -associated early, non-neoplastic nodule	82
Figure 2	Box Plot of the VEGF expression score in the different groups	84
Figure 3	Box Plot of the FGF expression score in the different groups	85
Figure 4	Box Plot of the PDGF expression score in the different groups	86
Figure 5	Box Plot of the mean microvessel count per high power field at the	
	periphery of the nodules	87
Figure 6	Box Plot of the mean microvessel count per high power field at the	
	centre of the nodules	88



# Figures – Chapter 7

Figure 1A	MAC387+ leukocytes in a non-neoplastic oesophageal nodule	109
Figure 1B	MAC387+ leukocytes in a Spirocerca lupi-induced oesophageal	
	osteosarcoma	109
Figure 1C	Diffuse distribution of CD3+ T lymphocytes in a Spirocerca lupi-	
	induced oesophageal undifferentiated sarcoma	109
Figure 1D	Focal/nodular distribution of CD3+ T lymphocytes in a Spirocerca	
	lupi-induced oesophageal undifferentiated sarcoma	109
Figure 1E	Pax5+ B lymphocytes in the same lymphoid focus at the periphery of	
	Spirocerca lupi-induced oesophageal undifferentiated sarcoma	109
Figure 1F	FoxP3+ cells in the same lymphoid focus at the periphery of	
	Spirocerca lupi-induced oesophageal undifferentiated sarcoma	109
Figure 1G	FoxP3+ cells in a bronchial lymph node, draining the distal	
	oesophageal osteosarcoma referred to in figure 1D	109
Figure 1H	CD3+ T lymphocytes in the same area of bronchial lymph node as	
	shown in figure 1G	109